Oxis International Inc. announced that it has reached agreement to restructure unregistered debt and equity securities that will eliminate more than 12 million warrants,$14.8 million of notes and all Series H and I Preferred Shares. Details of the restructure can be found in the company’s filed 8K report.
Oxis Chief Executive Officer and Chairman, Anthony Cataldo, said the completion of the restructuring will leave the company in sound financial shape to continue its Phase 1/Phase2 FDA clinical trial of OXS-1550, drug therapy for the treatment of Non-Hodgkins Lymphoma and leukemia. It also is a key step in getting the company’s stock approved for listing on the NASDAQ exchange, he said.
“Now it’s about science and delivery and going through the rigors of the FDA,” Cataldo said. “This is all part of our strategy to move forward our robust product pipeline.”
News of the debt restructuring follows the Nov. 23 announcement that the Food and Drug Administration had approved Oxis’ combination Phase 1/Phase 2 clinical trial of OXS-1550, the company’s promising therapy for Non-Hodgkins Lymphoma and leukemia. Oxis is collaborating with the University of Minnesota Masonic Cancer Center in the clinical trial.
Oxis holds worldwide exclusive rights to develop and commercialize OXS-1550.
“This helps pave the pathway toward funding the clinical trials,” Cataldo said of the debt restructuring. “We’re very excited about our drug for Non-Hodgkins Lymphoma and leukemia, and our partnership with the University of Minnesota.”
Cataldo is the founder and former Chairman and Chief Executive Office of Genesis Biopharma Inc., now known as Lion Biotechnologies [LBIO]. He led the company from February 2011 until June 2013, using assets purchased from the National Cancer Institute for the treatment of stage four melanoma. Today, Lion has a market capitalization of more than $314 million.
“Essentially, I’m using the same model that I used with Lion Biotechnologies to create Oxis,” Cataldo said.
Details of the debt restructuring are as follows:
Certain investors exchanged warrants to purchase 12,060,812 shares of Oxis capital stock and received one share of Oxis Common Stock.
Certain creditors of Oxis holding approximately $14,829,000 of outstanding debt (including accrued interest and penalties) have agreed to convert the debt into shares of Common Stock at a conversion price of $1.25 per share, upon successful completion by Oxis of a $6 million financing.
Certain investors together holding 25,000 shares of Series H Preferred Stock and 1,666,667 shares of Series I Preferred Stock have agreed to convert all such shares into an aggregate of approximately 4.075 million shares of Common Stock, upon successful completion by Oxis of a $6 million financing.
Certain investors also agree to a 1 year leak out provision which would only allow them to sell shares based on 10% of the previous days volume during this period of time.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
